Pfizer Inc. (NYSE:PFE) Shares Acquired by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 4.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,777,606 shares of the biopharmaceutical company’s stock after purchasing an additional 106,682 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Pfizer were worth $79,967,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in PFE. Front Street Capital Management Inc. grew its holdings in Pfizer by 4.3% during the 1st quarter. Front Street Capital Management Inc. now owns 5,168 shares of the biopharmaceutical company’s stock worth $268,000 after acquiring an additional 215 shares in the last quarter. Castleview Partners LLC grew its holdings in Pfizer by 2.4% during the 1st quarter. Castleview Partners LLC now owns 12,207 shares of the biopharmaceutical company’s stock worth $498,000 after acquiring an additional 287 shares in the last quarter. United Bank grew its holdings in Pfizer by 0.6% during the 1st quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock worth $2,416,000 after acquiring an additional 290 shares in the last quarter. Compton Capital Management Inc. RI grew its holdings in Pfizer by 0.5% during the 1st quarter. Compton Capital Management Inc. RI now owns 63,891 shares of the biopharmaceutical company’s stock worth $3,308,000 after acquiring an additional 300 shares in the last quarter. Finally, GHP Investment Advisors Inc. grew its holdings in Pfizer by 2.4% during the 4th quarter. GHP Investment Advisors Inc. now owns 13,332 shares of the biopharmaceutical company’s stock worth $683,000 after acquiring an additional 307 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the stock. TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a report on Thursday, January 4th. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Monday. Finally, Guggenheim initiated coverage on shares of Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective on the stock. Twelve investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $36.88.

Pfizer Trading Down 0.9 %

Shares of Pfizer stock traded down $0.23 during trading on Tuesday, hitting $25.68. The stock had a trading volume of 28,799,011 shares, compared to its average volume of 42,553,457. The stock has a 50 day simple moving average of $27.27 and a 200 day simple moving average of $28.84. The company has a market capitalization of $145.41 billion, a PE ratio of 71.69, a P/E/G ratio of 1.16 and a beta of 0.61. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a 1 year low of $25.61 and a 1 year high of $41.33.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. During the same period last year, the firm posted $1.14 earnings per share. The firm’s quarterly revenue was down 41.3% compared to the same quarter last year. On average, research analysts expect that Pfizer Inc. will post 2.22 EPS for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.